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Overview of pathogenesis of systemic sclerosis
D. J. Abraham1, T. Krieg2, J. Distler3 and O. Distler4
The aetiology of SSc is subject to ongoing research, as the precise events that underlie the development of this disease remain unclear.
The pathogenesis is known to involve endothelium, epithelium, fibroblasts, innate and adaptive immune systems and their component
immunological mediators. Endothelial cell damage may be the initiating factor, but the precise triggering event(s) remain elusive.
Angiogenesis also appears to be dysregulated. Vasculopathy shows similarities in different organs (e.g. pulmonary arterial hypertension,
renal disease, digital tip ulcers). Endothelin-1 is a potent mediator of vasculopathy, and hence represents a highly relevant target for
intervention of vascular features in SSc.
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Introduction
The aetiology of SSc is currently an expanding area of study, since
the exact nature of the events underlying this disease remains
unclear [1]. SSc may be initiated in the vasculature, with evidence
suggesting that some morphological changes may be apparent
before disease onset [1]. The pathological events in SSc may
include impaired communication between endothelial cells, epi-
thelial cells and fibroblasts; lymphocyte activation; autoantibody
production; inflammation; and connective tissue fibrosis [1]. These
events result in an accumulation of constituents of the extra-
cellular matrix (ECM), which replaces the normal tissue archi-
tecture, which in turn can culminate in organ failure. This review
will focus on the potential role of the epithelium, and the roles of
fibroblasts and immunological mediators in the pathogenesis of
SSc. In addition, this review will consider the mediators of tissue
remodelling, which are associated with the hallmark vasculopathy
of SSc.
The potential role of the epithelium
The epithelium can be found widespread throughout the body, as
the outer covering of the skin, and lining both internal organs and
body cavities (e.g. mucous membranes, gut and lungs). Conse-
quently, it has an extensive range of functions that include
secretion, absorption, protection, transcellular transport, sensa-
tion detection and selective permeability. Following tissue injury,
the epithelium plays a critical role in repairing wounds and
re-surfacing tissue. In patients with SSc, however, there is evidence
that this regeneration may be dysregulated.
Many epithelial-derived factors influence the behaviour of
fibroblasts, with some soluble mediators known to exhibit pro-
fibrotic activities, including TGF- and ET-1 (Table 1) [2, 3].
There is also evidence that epithelial-to-mesenchymal transdiffer-
entiation (EMT) occurs in lung fibrosis [4, 5], and this process is
known to be influenced or mediated by TGF-, and potentially
ET-1 [4–6].
During EMT, epithelial cells lose cell–cell attachment, alter
polarity, display specific surface markers and can undergo
cytoskeletal remodelling to exhibit a mesenchymal phenotype
[4]. Studies in vitro have shown that alveolar epithelial cells can
transdifferentiate into mesenchymal cells. Tissue staining and
transgenic animal studies have shown that alveolar epithelial cells
can co-express markers of both epithelial and mesenchymal cells,
including cadherin and -smooth muscle actin (-SMA) [5]. In
addition, in the murine bleomycin-induced lung fibrosis model
fibrosis is preceded by epithelial injury. These findings suggest
that the epithelium might play an important role in the patho-
genesis of SSc, at least for some specific organ manifestations such
as lung fibrosis (Fig. 1).
The role of fibroblasts and the immune system
The role of fibroblasts
Fibroblasts maintain the structural integrity of connective tissue,
secreting fibrillar procollagens, fibronectin and regulating the
turnover and composition of the ECM via highly specific pro-
teases such as collagenase. Different subtypes of fibroblasts exist
and can perform a variety of functions in different locations (e.g.
papillary fibroblasts, dermal papilla fibroblasts, myofibroblasts).
Although morphologically similar, these different fibroblast sub-
populations are distinguishable by their gene expression profiles
and functional activities [7, 8]. For example, whilst papillary
fibroblasts produce thin collagen bundles and have a high rate of
proliferation, reticular fibroblasts produce thick collagen bundles
and abundant versican, and promote rapid lattice contraction [9].
Following tissue injury, quiescent fibroblasts are activated during
the wound healing and inflammation phase, producing granula-
tion tissue and a provisional matrix, a process that is subsequently
reversed to remodel the scar. In human disease, such as
hypertrophic keloid scarring or SSc, this scar tissue is not
correctly terminated or remodelled resulting in excessive scar
formation.
Fibroblasts can be categorized according to different stages of
differentiation [10], as well as their levels of collagen production
[11]. In SSc patients, activated fibroblasts are responsible for the
development of fibrosis and accumulation of ECM molecules.
These fibroblasts are characterized by an overproduction of
collagen and the induction of collagen-modifying enzymes.
The gene expression profile of fibroblasts is influenced by their
environment [12]. For instance, quiescent fibroblasts express ET-1
and intercellular adhesion molecule-1, whereas the fibroblasts
subject to mechanical stress may express -SMA, TGF- and
ECM genes. The phenotype of SSc fibroblasts is comparable
with that of fibroblasts that have been exposed to excessive
signalling by TGF-, which suggests a potential underlying
mechanism [13, 14].
Activated fibroblasts may be derived from a number of origins.
Precursor or progenitor cells may be recruited from the bone
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marrow or circulation, and resident cells may be recruited locally
from the surrounding tissue. Although activated, these fibroblasts
may not be terminally differentiated and in cell culture they can
cease to exhibit an activated phenotype after several passages.
Activated fibroblasts in SSc may be derived from a number of
origins [15]. Mesenchymal precursor cells may be recruited from
the bone marrow via the circulation. Resident tissue-specific
precursors may also be utilized from the surrounding tissue
directly. Quiescent fibroblasts can be activated by different
mechanism(s) including: (i) direct cell–cell contact, (ii) stimulation
by soluble mediators following induction of the appropriate
receptor expression—including TGF-, connective tissue growth
factor (CTGF), PDGF or ET-1 [13, 16, 17]—or by (iii) modu-
lation of cell–matrix interactions. For example, ECM contraction
modulates the activity of mediators such as TGF-, and fibro-
blasts may also be activated by attachment to the ECM and the
resultant mechanical tension, which can contribute to a persistent
activation state [18]. Altered gene expression in SSc fibroblasts,
such as the expression of cartilage oligomeric matrix protein
and other key ECM components, is also likely to lead to a
disturbed macromolecular arrangement of ECM molecules
[19, 20]. These findings suggest a major role for fibroblasts in
the pathogenesis of SSc (Fig. 2).
The role of immunological mediators
The immune system is also implicated in the pathology of
SSc. Activated lymphocytes and autoantibodies are detectable
in SSc patients. Elevated levels of growth factors [including
TGF-, CTGF, vascular endothelial growth factor (VEGF),
fibroblast growth factor], ILs (including IL-2, IL-4, IL-6, IL-10,
IL-13), chemokines and cytokines [including monocyte chem-
oattractant protein-1 (MCP-1), IL-8, thymus and activation-
regulated chemokine, fractalkine and TNF-] are detectable in
this disease.
In patients with SSc, activated T lymphocytes are detectable
in both the circulation and the affected organs (skin and lung).
In the circulation, soluble IL-2 receptor levels correlate with
the extent of skin fibrosis [21] and there is evidence for clonal
expansion of T cells [22]. In the skin, oligoclonal expansion is
observed [23], and there is enhanced transendothelial migration of
CD4þ T cells [24].
The expression of CD19 on the circulating B cells of SSc
patients may be increased [25], as may the expression of CD80 and
CD86 on memory B cells [26]. Comparison of the cell type com-
position and gene expression profiles in skin biopsies from SSc
patients with normal individuals has revealed clear differences,
including infiltration of B lymphocytes into affected skin [19].
TABLE 1. Key cytokines in the induction of the fibrosis of SSc
Mediator Role in fibrogenesis
TGF- ECM production, fibroblast proliferation
and differentiation
CTGF Regulation of fibroblast proliferation and migration
and TGF--dependent ECM synthesis
ET-1 Regulation of ECM synthesis and contraction
Fibroblast growth factor Regulation of fibroblast growth
IL-1 Inflammatory mediator
IL-4 Regulation of collagen synthesis
IL-6 Regulation of -SMA expression in myofibroblasts
IL-12 Regulation of collagen synthesis
IL-13 Induction of TGF-
IL-17 Fibroblast proliferation
MCP-1 Inflammatory mediator and regulation of collagen
synthesis
MCP-3 Regulation of collagen synthesis
PDGF Regulation of TGF receptor expression, and fibroblast
and progenitor cell recruitment
FIG. 1. The role of the epithelium in the pathogenesis of SSc. BMDSC: bone marrow-derived stem cells.
FIG. 2. The role of fibroblasts in the pathogenesis of SSc.
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In the tight skin mouse model of SSc, experimental B-cell
depletion suppresses skin fibrosis and down-regulates Th2 cyto-
kines in the skin [27], which suggests a pathological role for B cells
in skin fibrosis.
The majority of patients with SSc exhibit circulating levels of
highly specific autoantibodies: one autoantibody group is directed
against nuclear antigens (topoisomerase, RNA polymerase),
whereas others may have a putative pathogenic role. This lat-
ter group includes anti-endothelial cell antibodies, which are
estimated to occur in 44–84% of SSc patients and may induce
apoptosis [28–31]. Anti-fibrillin-1 antibodies are detectable in
>50% of SSc patients and can activate fibroblasts and stimulate
release of TGF-. Antibodies to MMP-1 and -3 may also occur in
a high proportion of patients, preventing the degradation of
excessive collagen. Stimulatory anti-PDGF receptor antibodies
are detectable in SSc patients and are potentially pathogenic [16].
These autoantibodies may stimulate normal fibroblasts via
Ha–Ras pathways, generate reactive oxygen species cascades to
induce collagen I production and convert resting fibroblasts into
activated myofibroblasts. Altered B-cell function may therefore be
a key link between autoimmunity and fibrosis (Fig. 3).
Vasculopathy in SSc
In patients with SSc, vascular remodelling is dysregulated. In these
patients, vasculopathy may result from a disrupted or inappropri-
ate repair process following endothelial cell insult or injury. These
patients may exhibit up-regulation of vasoconstrictive, throm-
bogenic, mitogenic and pro-inflammatory factors, and down-
regulation of vasodilatory, anti-thrombogenic and anti-mitogenic
factors. This results in vasculopathy characterized by vasocon-
striction, adventitial and intimal proliferation, inflammation and
thrombosis.
Vasculopathy involves all layers of the vessel wall, and is
characterized by fibrotic intimal hyperplasia [32]. As a result,
vessels lose their elasticity and become narrower. In time, the
arterial intima may thicken and occlusion of the small arteries can
facilitate the formation of in situ thrombosis. Although the
vasculopathy of SSc clearly shows organ-specific features, there
are a number of similarities in the pathogenesis and morphology.
Fibrosis typically begins in the media of medium-sized arteries,
extending into the intima and adventitia and disrupting elasticity.
The typical plexiform lesions of pulmonary arterial hypertension,
comprising endothelial cells and myofibroblasts, can occur at all
stages of development and healing. In renal arteries of patients
with scleroderma renal crisis [33], there is the characteristic over-
growth of the endothelium and deposition of scar tissue in the
blood vessels [34]. In digital ulceration associated with SSc,
vascular remodelling leads to progressive occlusion of the blood
vessels. Together with the reduced capillary density, this results in
hypoxia, necrosis and tissue loss [35].
The processes underlying vasculopathy
Vascular remodelling appears to be preceded by endothelial dys-
function. Consistent evidence suggests that microvascular endo-
thelial cell activation and damage is ubiquitous and occurs early
in SSc. Activated endothelial cells express adhesion molecules,
which, in part, promote perivascular inflammatory infiltrates by
enabling the transmigration of inflammatory cells through the
endothelium. Platelets are also activated.
The identity of the initial trigger remains elusive [36]. Hypo-
theses for the method of primary activation of endothelial cells
in SSc include autoantibodies showing cross-reactivity between
CMV epitopes and specific surface molecules of endothelial cells,
inducing apoptosis. However, this is unlikely to be the sole
aetiological factor, since CMV is ubiquitous in the normal
population. Anti-endothelial cell antibodies can also activate
endothelial cells, inducing the production of adhesion mole-
cules and cytokines, such as IL-1 and TNF-. However, anti-
endothelial cell antibodies are detected in a variety of vascular
diseases and specific epitopes and mechanisms have not been
clarified in SSc. Oxidative stress and the presence of elevated levels
of reactive oxygen species (ROS) has also been suggested to be an
essential element in the early vascular pathogenesis in SSc, but the
precise source of the ROS remains unknown.
Whatever the primary cause of the initial activation, ongoing
activation inevitably results in endothelial cell damage. Apoptosis
is an early event, and, if endothelial cells are not replaced by new
cells, capillary breakdown and the typical clinical manifestations
of vasculopathy can result.
A physiological reaction pattern to capillary breakdown and
resulting tissue hypoxia is angiogenesis, a finely balanced process
involving both angiogenic and angiostatic factors. In patients with
SSc, angiogenesis becomes dysregulated. Angiogenic factors,
including PDGF, VEGF, ET-1, TGF-, MCP-1 and urokinase-
type plasminogen activator receptors are up-regulated in SSc,
despite the lack of sufficient angiogenic responses in ischaemic
tissues of SSc patients.
VEGF is over-expressed throughout the dermis and epidermis,
including fibroblasts and perivascular cells [37]. VEGF receptor-1
(VEGFR-1) and VEGFR-2 are also up-regulated [37]. However,
while VEGF is one of the strongest angiogenic factors known in
biology, its duration of expression is of critical importance: an
uncontrolled, chronic over-expression, as in SSc, might lead to
deleterious effects rather than promote the formation of new
vessels. Alternatively, the up-regulated angiogenic factors could be
overwhelmed by an even greater up-regulation of angiostatic
FIG. 3. The role of immunological mediators in the pathogenesis of SSc.
Pathogenesis of SSc iii5
factors, such as angiostatin and endostatin [38, 39]. At present,
data describing the dysregulation of angiogenic homeostasis are
incomplete and need further research.
The relationship between blood vessels, endothelium and
pericytes
Small blood vessels comprise two cell types: endothelial cells and
their attendant pericytes. To date, vascular research in SSc has
been focused on the role of the endothelial cells in SSc patho-
genesis, with the pericyte being largely overlooked. Microvascular
pericytes are in intimate contact with, and modulate the func-
tion of, endothelial cells. They may also constitute a cellular link
between microvascular damage and fibrosis by transdifferentiat-
ing into myofibroblasts [40]. In patients with SSc, pericytes
are hyperplasic [41] and activated [40, 42]. Such pericytes may
contribute to the overproduction of ECM molecules, and
angiopoietin/Tie-2 signalling might be impaired.
ET-1 as a molecular target for intervention in the
management of patients with SSc
ET-1 is a highly potent vasoconstrictor that is produced by
endothelial cells and is a key mediator of vasculopathy. ET-1
promotes cell growth, arterial wall thickening and endothelial cell
dysfunction, resulting in decreased levels of nitric oxide. ET-1 can
stimulate the proliferation of pulmonary artery smooth muscle
cells [43, 44], fibroblast collagen production, the down-regulation
of MMP-1 and the contraction of fibroblast-populated collagen
lattices; all of which suggest an important role in fibrosis.
Increased ET-1 production can trigger an inflammatory cascade,
elevating the plasma levels of pro-inflammatory cytokines in
patients with pulmonary arterial hypertension [45]. Thus, ET-1
promotes vasoconstriction and contributes to cardiac and
vascular hypertrophy, inflammation and fibrosis [46].
ET-1 is over-expressed in both early- and late-stage SSc [1].
Increased expression of ET-1 and ET-1 receptors is detectable in
pre-sclerotic and early diffuse skin lesions [47], and elevated levels
of ET-1 have been found in the blood vessels, lungs, kidneys and
skin of SSc patients [48]. A role in the pathogenesis of SSc is
suggested by the finding that circulating levels of ET-1 correlate
with skin fibrosis and duration of disease [47].
ET-1 mediates its biological effects via the ETA and ETB
receptors. ETA receptors are expressed by vascular smooth mus-
cle cells and can mediate vasoconstriction, smooth muscle cell
proliferation, fibrosis and inflammation. ETB receptors are
predominantly expressed on endothelial cells; they can mediate
vasodilation via the release of nitric oxide or potassium channel
activation, and can remove ET-1 from the circulation. ETB
receptors are also present on smooth muscle cells; however, in this
localization they behave similarly to ETA receptors [49].
In vasculopathic conditions such as SSc, ETB receptors are
down-regulated on endothelial cells, which may diminish their
vasodilatory role. On smooth muscle cells, ETB receptors are up-
regulated, and can contribute to cell proliferation, hypertrophy,
inflammation, fibrosis and vasoconstriction [48, 50].
Conclusion
The pathogenesis of SSc is complex and appears to involve
endothelium, epithelium, fibroblasts and immunological media-
tors, resulting in dysregulated vascular remodelling and, ulti-
mately, vasculopathy. Endothelial cell injury is an early and
probably initiating event, but the precise aetiology remains
unclear. There are similarities between the vasculopathies of dif-
ferent organs, including pulmonary arterial hypertension, scler-
oderma renal crisis and digital ulcers, of which ET-1 is believed to
be an important mediator. ET-1 is over-expressed in patients with
SSc, and its serum plasma concentrations correlate with markers
of disease severity. ET-1 therefore represents an important
molecular target for therapeutic intervention in the vascular
disease manifestations of SSc.
Acknowledgements
The authors received editorial assistance from Elements
Communications, supported by an educational grant from
Actelion Pharmaceuticals Limited (Allschwil, Switzerland).
Supplement: This paper forms part of the supplement entitled ‘Ten
years of partnership: translating ideas into progress in systemic
sclerosis’. This supplement was supported by an unrestricted grant
from Actelion Pharmaceuticals Ltd.
Disclosure statement: O.D. is a consultant for, has received
support or honoraria from Actelion, Encysive, Array and
Ergonex. J.D. is a member of a Speakers’ Bureau for Actelion
and Encysive and has received research grants/support from
Novartis, Bristol-Myers Squibb and Celgene. D.J.A. has received
speaker fees and travel expenses from Actelion Biopharma-
ceuticals and Encysive Pharmaceuticals. T.K. has received speaker
fees and reimbursement for travel expenses from Actelion Phar-
maceuticals Ltd and Encysive.
References
1 Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin
in systemic sclerosis. Arthritis Res Ther 2007;9(Suppl. 2):S2.
2 Shi-Wen X, Denton CP, Dashwood MR et al. Fibroblast matrix gene expression
and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:
417–25.
3 Denton CP. Therapeutic targets in systemic sclerosis. Arthritis Res Ther 2007;
9(Suppl. 2):S6.
4 Willis BC, du Bois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in
the lung. Proc Am Thorac Soc 2006;3:377–82.
5 Kim KK, Kugler MC, Wolters PJ et al. Alveolar epithelial cell mesenchymal transition
develops in vivo during pulmonary fibrosis and is regulated by the extracellular
matrix. Proc Natl Acad Sci USA 2006;103:13180–5.
6 Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelial-
mesenchymal transition through endothelin type A receptor-mediated production of
TGF-beta 1. Am J Respir Cell Mol Biol 2007;37:38–47.
7 Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic demarcation by
positional variation in fibroblast gene expression programs. PLoS Genet 2006;
2:e119.
8 Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The
myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807–16.
9 Sorrell JM, Caplan AI. Fibroblast heterogeneity: more than skin deep. J Cell Sci
2004;117:667–75.
10 Bayreuther K, Rodemann HP, Hommel R et al. Human skin fibroblasts in vitro
differentiate along a terminal cell lineage. Proc Natl Acad Sci USA 1988;85:5112–6.
11 LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a
possible defect in the regulation or activation of the scleroderma fibroblast. J Clin
Invest 1974;54:880–9.
12 Kessler-Becker D, Krieg T, Eckes B. Expression of pro-inflammatory markers by
human dermal fibroblasts in a three-dimensional culture model is mediated by an
autocrine interleukin-1 loop. Biochem J 2004;379:351–8.
13 Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression
of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of
autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998;
110:47–51.
14 Sonnylal S, Denton CP, Zheng B et al. Postnatal induction of transforming growth
factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and
biochemical features of scleroderma. Arthritis Rheum 2007;56:334–44.
15 Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and
myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep
2007;9:136–43.
Rheumatology key messages
 The pathogenesis of SSc involves epithelium, fibroblasts and
immunological mediators.
 Endothelial cell damage is likely to be the initiating factor.
 ET-1 is a potent mediator of vasculopathy and a therapeutic
target.
iii6 D. J. Abraham et al.
16 Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF
receptor in systemic sclerosis. N Engl J Med 2006;354:2667–76.
17 Chen Y, Shi-Wen X, Eastwood M et al. Contribution of activin receptor-like kinase 5
(transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of
scleroderma fibroblasts. Arthritis Rheum 2006;54:1309–16.
18 Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent
TGF-1 from the extracellular matrix. J Cell Biol 2007;179:1311–23.
19 Whitfield ML, Finlay DR, Murray JI et al. Systemic and cell type-specific
gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:
12319–24.
20 Gardner H, Shearstone JR, Bandaru R et al. Gene profiling of scleroderma skin
reveals robust signatures of disease that are imperfectly reflected in the transcript
profiles of explanted fibroblasts. Arthritis Rheum 2006;54:1961e–73.
21 Steen VD, Engel EE, Charley MR et al. Soluble serum interleukin 2 receptors in
patients with systemic sclerosis. J Rheumatol 1996;23:646–9.
22 French LE, Lessin SR, Addya K et al. Identification of clonal T cells in the blood of
patients with systemic sclerosis: positive correlation with response to photopheresis.
Arch Dermatol 2001;137:1309–13.
23 Sakkas LI, Xu B, Artlett CM et al. Oligoclonal T cell expansion in the skin of patients
with systemic sclerosis. J Immunol 2002;168:3649–59.
24 Stummvoll GH, Aringer M, Grisar J et al. Increased transendothelial migration of
scleroderma lymphocytes. Ann Rheum Dis 2004;63:569–74.
25 Sato S, Hasegawa M, Fujimoto M et al. Quantitative genetic variation in CD19
expression correlates with autoimmunity. J Immunol 2000;165:6635–43.
26 Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte
homeostasis in systemic sclerosis: expanded naive B cells and diminished but
activated memory B cells. Arthritis Rheum 2004;50:1918–27.
27 Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin
fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J
Pathol 2006;169:954–66.
28 Rosenbaum J, Pottinger BE, Woo P et al. Measurement and characterisation of
circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol
1988;72:450–6.
29 Hill MB, Phipps JL, Cartwright RJ et al. Antibodies to membranes of endothelial cells
and fibroblasts in scleroderma. Clin Exp Immunol 1996;106:491–7.
30 Salojin KV, Le Tonqueze M, Saraux A et al. Antiendothelial cell antibodies: useful
markers of systemic sclerosis. Am J Med 1997;102:178–85.
31 Ahmed SS, Tan FK, Arnett FC et al. Induction of apoptosis and fibrillin 1 expression
in human dermal endothelial cells by scleroderma sera containing anti-endothelial
cell antibodies. Arthritis Rheum 2006;54:2250–62.
32 Humbert M, Morrell NW, Archer SL et al. Cellular and molecular patho-
biology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl.
S):13S–24S.
33 Penn H, Howie AJ, Kingdon EJ et al. Scleroderma renal crisis: patient characteristics
and long-term outcomes. Q J Med 2007;100:485–94.
34 Rhew EY, Barr WG. Scleroderma renal crises: new insights and developments. Curr
Rheumatol Rep 2004;6:129–36.
35 LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am
1996;22:675–94.
36 Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected
rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther
2007;(9 Suppl. 2):S3.
37 Distler O, Distler JH, Scheid A et al. Uncontrolled expression of vascular endothelial
growth factor and its receptors leads to insufficient skin angiogenesis in patients with
systemic sclerosis. Circ Res 2004;95:109–16.
38 Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased
concentrations of the circulating angiogenesis inhibitor endostatin in patients with
systemic sclerosis. Arthritis Rheum 2000;43:889–93.
39 Distler O, Del Rosso A, Giacomelli R et al. Angiogenic and angiostatic factors in
systemic sclerosis: increased levels of vascular endothelial growth factor are a
feature of the earliest disease stages and are associated with the absence of fingertip
ulcers. Arthritis Res 2002;4:R11.
40 Rajkumar VS, Howell K, Csiszar K et al. Shared expression of phenotypic markers in
systemic sclerosis indicates a convergence of pericytes and fibroblasts to a
myofibroblast lineage in fibrosis. Arthritis Res Ther 2005;7:R1113–23.
41 Helmbold P, Fiedler E, Fischer M, Marsch WC. Hyperplasia of dermal microvascular
pericytes in scleroderma. J Cutan Pathol 2004;31:431–40.
42 Rajkumar VS, Sundberg C, Abraham DJ et al. Activation of microvascular pericytes
in autoimmune Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum
1999;42:930–41.
43 Hassoun PM, Thappa V, Landman MJ, Fanburg BL. Endothelin 1: mitogenic activity
on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells.
Proc Soc Exp Biol Med 1992;199:165–70.
44 Stelzner TJ, O’Brien RF, Yanagisawa M et al. Increased lung endothelin-1 production
in rats with idiopathic pulmonary hypertension. Am J Physiol 1992;262:L614–20.
45 Dorfmu¨ller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial
hypertension. Eur Respir J 2003;22:358–63.
46 Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr
Res 2005;57:16R–20R.
47 Vancheeswaran R, Magoulas T, Efrat G et al. Circulating endothelin-1 levels
in systemic sclerosis subsets–a marker of fibrosis or vascular dysfunction?
J Rheumatol 1994;21:1838–44.
48 Abraham DJ, Vancheeswaran R, Dashwood MR et al. Increased levels of
endothelin-1 and differential endothelin type A and B receptor expression in
scleroderma-associated fibrotic lung disease. Am J Pathol 1997;151:831–41.
49 Shetty SS, Okada T, Webb RL et al. Functionally distinct endothelin B receptors in
vascular endothelium and smooth muscle. Biochem Biophys Res Commun 1993;
191:459–64.
50 Bauer M, Wilkens H, Langer F et al. Selective upregulation of endothelin B receptor
gene expression in severe pulmonary hypertension. Circulation 2002;105:1034–6.
Pathogenesis of SSc iii7
